View the full agenda: https://www.cphi.com/europe/en/attend/attend/conference-agenda.html
USP participation
Tuesday, October 28, 2025 from 11:10 AM to 11:50 AM in Hall 4 – Europa Room Pharma's Global Economic Outlook: Balancing Regional Challenges with International Opportunities
Speakers
Ronald T. Piervincenzi, Chief Executive Officer (CEO), U.S. Pharmacopeia
Markus Sieger, CEO, Polpharma Group Holding BV
Greg Behar, CEO, Recipharm
Christian Seufert, Head of Advanced Synthesis, Lonza Group Ltd
Patrick Dixon, Chairman, Global Change Ltd
Tuesday, October 28, 2025 from 4:00 PM to 4:45 PM in Hall 4.1 – 4.1L8
Continuous Manufacturing: A View Into the Future of Pharmaceuticals Production
Speakers
Edgar A. Pogna, Director, L.E.K. Consulting
Gabriela Grasa Mannino, Programs Director, U.S. Pharmacopeia
Salvatore Mascia, CEO, CONTINUUS Pharmaceuticals
Rohtash Kumar, Senior Vice President, Development Operations & Chief Technology Officer, Veranova
Philip Coetzee, Director CMO Management, Daichii Sankyo
Continuous manufacturing: A view into the Future of Pharmaceuticals Production Pharmaceutical manufacturing is evolving. As the industry looks for ways to enhance efficiency, improve quality, and strengthen supply chains, continuous manufacturing is emerging as a powerful alternative to traditional batch production. Though adoption has been gradual, CM is gaining momentum across pharma and CDMOs — backed by growing regulatory support and real-world successes.
L.E.K. Consulting together with a panel of industry experts will explore several topics around CM to bring a perspective on the current State-of-the-Art for continuous manufacturing, including: - Why and When Is CM Interesting? - What are the Challenges and Opportunities? - How are regulators reacting? - What is the Outlook for Continuous Manufacturing?
Wednesday, October 29, 2025 from 4:30 PM to 4:45 PM
Navigating Emerging Contaminants: Nitrosamines
Naiffer Romero, Principal Scientist, U.S. Pharmacopeia
Nitrosamine impurities – potent, regulatory-scrutinized carcinogens – can arise throughout the drug lifecycle via amine–nitrite reactions during API synthesis, in-process nitrosation, or post-pack degradation. This talk distills the essentials: how and where nitrosamines form; current ICH M7, FDA, and EMA expectations for assessing and setting limits; analytical challenges during confirmatory testing, and exploration of the risk-based mitigation tools that marries synthetic-route redesign, raw-material controls, and data-driven process optimization.